Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A
نویسندگان
چکیده
BACKGROUND Hemophilia A is a congenital bleeding disorder caused by defective or deficient factor VIII (FVIII). The active form of FVIII is the co-factor for the serine protease factor IXa (FIXa) in the membrane-bound intrinsic tenase (FVIIIa-FIXa) complex. The assembly of the FVIIIa-FIXa complex on the activated platelet surface is critical for successful blood clotting. OBJECTIVES To characterize the role of lipid nanodiscs (ND) for on FVIII function in vivo and test the lipid ND as a delivery system for FVIII. To evaluate the potential of binding recombinant FVIII to ND as improved treatment for Hemophilia A. METHODS Recombinant porcine FVIII (rpFVIII) was expressed and characterized in solution, and when bound to ND. The rpFVIII, ND and rpFVIII-ND complexes were characterized via transmission electron microscopy. Functional studies were carried out using aPTT tests and time resolved tail snip studies of hemophilic mice. RESULTS Functional rpFVIII was successfully assembled on lipid ND. When injected in hemophilic mice, the rpFVIII-ND complexes showed a pronounced pro-coagulant effect, which was stronger than that of rpFVIII alone. While injection of the ND alone showed a pro-coagulant effect this effect was not additive, implying that the rpFVIII-ND complexes have a synergistic effect on the clotting process in hemophilic mice. CONCLUSIONS Binding of rpFVIII to ND prior to its injection in hemophilic mice significantly improves the therapeutic function of the protein. This represents a meaningful step towards a new approach to modulate blood coagulation at the membrane-bound FVIII level and the assembly of the intrinsic tenase complex.
منابع مشابه
Detection of Factor VIII Inhibitors in Hemophilia A Patients
Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...
متن کاملHepatitis Viruses Seromarkers and Liver Function inGuilan Hemophiliacs
Abstract There are some reports about hepatitis B and C Virus infection in hemophiliacs in different part of our country. We studied Guilan Province hemophiliacs to determine the frequency of hepatitis B surface antigen (HbsAg), anti hepatitis C antibody and liver function test impairments. This study was done from Feb to Apr 1999 among hemophiliacs registered in Guilan Hemophilia Society. Pat...
متن کاملفراوانی هپاتیتB ، هپاتیتC و ارتباط آنها با ایجاد مهار کننده فاکتور VIII در مبتلایان هموفیلی استان همدان- 1383
Abstract: Background: Hemophilia is a x-linked deficiency of factor VIII. The aim of the present study was to determine the frequencies of hepatitis B and C infections, markers of inflammation and liver function tests and also to assess the possible association between factor VIII inhibitor and hepatitis B and C infections in hemophiliacs of Hamedan Province of Iran. Materials and methods: Si...
متن کاملGenetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
Patients with severe coagulation factor VIII deficiency require frequent infusions of human factor VIII (hFVIII) concentrates to treat life-threatening hemorrhages. Because these patients are immunologically hFVIII-naive, a significant treatment complication is the development of inhibitors or circulating alloantibodies against hFVIII, which bind the replaced glycoprotein, increase its plasma c...
متن کامل